Checklist of items retained from the STROBE statement.

<p>Checklist of items retained from the STROBE statement.</p

Flow diagram of study selection process.

<p>Flow diagram of study selection process.</p

Characteristics of the studies presenting incidence rate of switching to second-line ART.

<p>Characteristics of the studies presenting incidence rate of switching to second-line ART.</p

Characteristics of the studies presenting incidence rate of switching to second-line ART.

**<p>as stated in the article.</p><p>NA: not available.</p

Characteristics of the studies presenting incidence rate of switching to second-line ART.

<p>NA: not available.</p

Quantification and identification of the bacterial flora present on the transducers.

<p>Quantification and identification of the bacterial flora present on the transducers.</p

Improvement of CSA after 4 months of Equitend^® treatment.

<p>Graphics represent CSA (cm²) at the time of inclusion (M0) and after 4-months (M4) treatment for each horse in placebo group (left panel) and Equitend^®-treated group (right panel). The table represent the number of horses in each treated group that improved more than 10% the CSA (■), not improved (■ Decrease or increase of CSA less than 10%), or worsened more than 10% (■). Data were compared by asymptotic Cochran-Armitage test.</p

Equitend^®-treated horses have better performances and recovery compared to placebo a year before tendinitis and over the two years after inclusion.

<p>Equitend^®-treated horses have better performances and recovery compared to placebo a year before tendinitis and over the two years after inclusion.</p

Mean CSA measures before and during the first four months of treatment.

<p>Mean CSA measures before and during the first four months of treatment.</p

Chemical structure of Equitend^® active substance OTR4131.

<p>OTR4131 is an alpha 1–6 carboxymethyl sulfate acetate glucose polymer with a molecular weight ranged between 100 to 150 kDa.</p